1Manns MP,McHutehison JG,Gordon SC,et al.Peginterferon alfa2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet,2001,358:958-965.
2Fried MW,Shiffman ML,Reddy KR,et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med,2002,347:975-982.
3MuirAJ,Bornstein JD,Killenberg PG,et al.Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.N Engl J Med,2004,350:2265-2271.
4Conjeevaram HS,Fried MW,Jeffers LI,et al.Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C ganotype 1.Gastroenterology,2006,131:470-477.
5Lee SS,Heathcote EJ,Reddy KR,et al.Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)J Hepatol,2002,37:500-506.
6Fried MW,Jensen DM,Rodriguez-Torres M,et al.Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics:randomized study of higher doses of peginterferon aipha-2a and ribavirin.Hepatology,2008,48:1033-1043.
7Reau N,DeVoss A,Elsen C,et al.Evauation of early null-response (ENV) as a predictor of nonresponse to PEG RBV in patients with HCV.AASLD,2008,San Francisco.Abstract 1247.
8Ferenci P,Fried MW,Shiffman ML,et al.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.J Hepatol,2005,43:425-433.
9Samchez-Tapias JM,Diago M,Escarttn P,et al.Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.Gastroenterology,2006,131:451-460.
10Shiffman ML,Ghany MG,Morgan TR,et al.Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.Gastroenterology,2007,132:103-112.
